Pfizer (NYSE:PFE) Trading 1.8% Higher – Should You Buy?

Pfizer Inc. (NYSE:PFE) was up 1.8% during trading on Thursday . The stock traded as high as $26.91 and last traded at $26.7450. Approximately 38,382,237 shares were traded during mid-day trading, a decline of 11% from the average daily volume of 42,983,527 shares. The stock had previously closed at $26.26.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage ELREXFIO Phase‑3 win — MagnetisMM‑5 showed a statistically significant improvement in progression‑free survival for relapsed/refractory multiple myeloma, strengthening Pfizer’s oncology pipeline and potential longer‑term sales upside. Pfizer’s blood cancer drug meets main goal in late-stage trial (Reuters)
• Positive Sentiment: VYNDAMAX patent settlement extends U.S. protection to 2031 — agreements with several generic makers delay generic entry and protect a ~$6.4B franchise, reducing near‑term downside risk to cash flows from that asset. Pfizer (PFE) Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031 (Yahoo)
• Positive Sentiment: Market takeaway / analyst attention — multiple outlets and analysts are flagging these wins as material, which can support sentiment and reduce valuation risk tied to those franchises. Pfizer Just Scored a Win That Wall Street Can’t Ignore (The Motley Fool)
• Neutral Sentiment: Upcoming Q1 earnings (May 5) create event risk — Wall Street and outlets are highlighting estimates and key metrics to watch; short‑term volatility is likely until results. Zacks consensus: sales ~$13.82B and EPS ~$0.74 for Q1. Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q1 Earnings (Zacks)
• Neutral Sentiment: Market opportunity notes — sector reports list Pfizer among incumbents in growing OTC segments (e.g., dry‑eye drops), which is a modest, longer‑term tailwind but not immediately material to stock moves. $4+ Billion OTC Dry Eye Drops Market Analysis Report 2026 (Yahoo / GlobeNewswire)
• Negative Sentiment: Competitive pressure from Alnylam — Alnylam’s strong Amvuttra quarter (stock surge) highlights competitive dynamics in related therapeutic areas and could weigh on expectations for market share where Pfizer competes. Alnylam Surges After Its Pfizer-Rivaling Blockbuster Jumps Nearly 200% (Yahoo)
• Negative Sentiment: Minor analyst estimate trim — Erste Group slightly reduced its FY2027 EPS forecast (small downward revision), a reminder analysts are still refining medium‑term numbers even after positive data and settlements.

Wall Street Analyst Weigh In

Several research analysts recently commented on PFE shares. CICC Research assumed coverage on shares of Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. Bank of America dropped their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. BMO Capital Markets reissued an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a research report on Monday, March 9th. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $28.74.

Pfizer Stock Performance

The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $152.08 billion, a P/E ratio of 19.67 and a beta of 0.43. The business’s 50 day simple moving average is $27.17 and its two-hundred day simple moving average is $26.09.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the prior year, the firm posted $0.63 earnings per share. The business’s revenue was down 1.2% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer’s dividend payout ratio (DPR) is presently 126.47%.

Institutional Investors Weigh In On Pfizer

Several institutional investors have recently modified their holdings of PFE. Vermillion Wealth Management Inc. grew its stake in shares of Pfizer by 19.4% in the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 382 shares during the period. Triad Wealth Partners LLC grew its position in shares of Pfizer by 1.9% during the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after acquiring an additional 386 shares during the period. Eagle Capital Management LLC increased its position in Pfizer by 0.3% in the first quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after buying an additional 390 shares in the last quarter. ETF Store Inc. increased its holdings in Pfizer by 3.8% in the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after acquiring an additional 396 shares in the last quarter. Finally, Mattern Wealth Management LLC increased its holdings in Pfizer by 4.6% in the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after acquiring an additional 400 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.